Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Down 5.3%

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) traded down 5.3% during mid-day trading on Wednesday . The company traded as low as $1.08 and last traded at $1.08. 126,750 shares traded hands during trading, a decline of 93% from the average session volume of 1,761,175 shares. The stock had previously closed at $1.14.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Adaptimmune Therapeutics in a research report on Friday, December 29th. They set a "hold" rating for the company.

Adaptimmune Therapeutics Trading Down 5.3 %

The stock has a 50-day simple moving average of $1.39 and a 200-day simple moving average of $0.92. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -1.96 and a beta of 2.39.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last announced its earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.12). Adaptimmune Therapeutics had a negative net margin of 188.90% and a negative return on equity of 155.39%. The firm had revenue of $0.23 million for the quarter, compared to the consensus estimate of $4.80 million. As a group, research analysts expect that Adaptimmune Therapeutics plc will post -0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Columbia Advisory Partners LLC bought a new position in Adaptimmune Therapeutics during the first quarter valued at about $25,000. JTC Employer Solutions Trustee Ltd bought a new position in Adaptimmune Therapeutics during the first quarter valued at about $41,000. Twin Focus Capital Partners LLC purchased a new stake in shares of Adaptimmune Therapeutics during the fourth quarter valued at $44,000. Barclays PLC purchased a new stake in shares of Adaptimmune Therapeutics during the second quarter valued at $46,000. Finally, Marquette Asset Management LLC purchased a new stake in shares of Adaptimmune Therapeutics during the third quarter valued at $77,000. Institutional investors own 31.37% of the company's stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.